In focus
Samsung Biologics Earns 'Negligible Risk' ESG Rating, Joins Top 0.5% in Pharma
Samsung Biologics achieved a 9.0 ESG Risk Rating from Morningstar Sustainalytics, moving from 'Low Risk' to 'Negligible Risk' and ranking among the top 0.5% in the pharmaceuticals industry. The upgrade reflects stronger environmental, safety, quality, and ethics management across its global CDMO operations.
Read the story